公开(公告)号：US20230310388A1

公开(公告)日：2023-10-05

申请号：US17996655

申请日：2021-04-23

申请人： Neoculi Pty Ltd

发明人： Stephen Page ,  Adam McCluskey ,  Martine Keenan ,  Andrew Stevens ,  Sanjay Garg

IPC分类号： A61K31/433 ,  A61K31/498 ,  A61K31/428 ,  A61K31/4709 ,  A61K31/4164 ,  A61K31/245 ,  A61P31/10

CPC分类号： A61K31/433 ,  A61K31/498 ,  A61K31/428 ,  A61K31/4709 ,  A61K31/4164 ,  A61K31/245 ,  A61P31/10

摘要： Provided herein are methods of treating or preventing a fungal colonisation or infection in a subject. The method includes administering a therapeutically effective amount of a compound, or a therapeutically acceptable salt thereof, to the subject, wherein the fungal colonisation or infection is caused by a fungal agent. In certain embodiments, the compound is a compound of Formula I, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof:

公开(公告)号：US11738006B2

公开(公告)日：2023-08-29

申请号：US17125591

申请日：2020-12-17

申请人： SATO PHARMACEUTICAL CO., LTD.

发明人： Masahiro Ito ,  Kiyotaka Matsui ,  Masami Inuma

IPC分类号： A61K31/4178 ,  A61K47/12 ,  A61K47/22 ,  A61K47/08 ,  A61K9/00 ,  A61P31/10 ,  A61K47/10 ,  A61K47/32

CPC分类号： A61K31/4178 ,  A61K9/0014 ,  A61K47/08 ,  A61K47/10 ,  A61K47/12 ,  A61K47/22 ,  A61K47/32 ,  A61P31/10

摘要： The present invention provides a technique that allows a pharmaceutical composition, preferably for external use, containing luliconazole or the like to contain luliconazole or the like at a high concentration, and suppresses the precipitation thereof over time. The present invention uses a polyethylene glycol having an average molecular weight of 380 to 420 represented by a formula HOCH2(CH2OCH2)nCH2OH (where n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone in combination with the luliconazole or the like.

公开(公告)号：US11731939B1

公开(公告)日：2023-08-22

申请号：US18118280

申请日：2023-03-07

申请人： KING FAISAL UNIVERSITY

发明人： Christophe Tratrat ,  Michelyne Haroun

IPC分类号： C07D209/40 ,  A61P31/10 ,  A61P31/06 ,  C07D403/08

CPC分类号： C07D209/40 ,  A61P31/06 ,  A61P31/10 ,  C07D403/08

摘要： The indole-based chalcone compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.

公开(公告)号：US11730717B1

公开(公告)日：2023-08-22

申请号：US17374535

申请日：2021-07-13

申请人： The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges

发明人： Toby Larue Nelson ,  Santosh Adhikari ,  Erika Lutter ,  Karen Wozniak

IPC分类号： A61K31/404 ,  A61K31/04 ,  A61K31/10 ,  A01N43/38 ,  A61P31/04 ,  A61P31/10

CPC分类号： A61K31/404 ,  A01N43/38 ,  A61P31/04 ,  A61P31/10

摘要： Herein, is taught a Eumelanin-inspired antimicrobial capable of overcoming methicillin resistant Staphylococcus aureus (MSRA) and Enterococcus faecalis. By ligating quaternary ammonium functionalized “arms” on to a Eumelanin-inspired indole, with intrinsic antimicrobial activity, a cell wall destroying antimicrobial agent was prepared. It also has antifungal effects against Candida albicans. Further, Eumelanin-inspired phenyleneethynylene (EIPE) derivatives EIPE-1 and EIPE-HCl are novel compounds. EIPE structure serves as scaffolding for functional groups that may have antibacterial properties. Both gram-positive and gram-negative organisms are screened against EIPE derivatives using a standardized Kirby Bauer disk agar diffusion assay. These results showed that EIPE-1 has antibacterial properties against some pathogenic gram-positive organisms.

公开(公告)号：US20230218713A1

公开(公告)日：2023-07-13

申请号：US17784589

申请日：2020-12-10

申请人： Washington University

发明人： Thaddeus Stappenbeck ,  Umang Jain

IPC分类号： A61K38/12 ,  A61K31/4196 ,  A61K31/513 ,  A61P31/10 ,  A61P1/04

CPC分类号： A61K38/12 ,  A61K31/4196 ,  A61K31/513 ,  A61P31/10 ,  A61P1/04

摘要： Methods for treating, selecting a treatment, and monitoring a treatment for an inflammatory bowel disease in a patient in need are disclosed. Treatments include administering an antifungal compound. The method for selecting and monitoring a treatment includes detecting a biomarker indicative of an amount of the fungus Debaryomyces hansenii within the sample. The treatment is administered if the biomarker is above a threshold level and the biomarker may be monitored before and during treatment. Biomarkers include abundance of fungal DNA in the patient's gut microbiota and anti-fungal antibodies in the blood of the patient.

公开(公告)号：US20230218652A1

公开(公告)日：2023-07-13

申请号：US17927941

申请日：2021-05-28

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  NANTES UNIVERSITÉ

发明人： ARNAUD TESSIER ,  PATRICE LE PAPE ,  JACQUES LEBRETON ,  FABRICE PAGNIEZ ,  GILLES-OLIVIER GRATIEN

IPC分类号： A61K31/7048 ,  A61P31/10

CPC分类号： A61K31/7048 ,  A61P31/10

摘要： The invention relates to an antifungal prodrug which comprises an antifungal moiety which is linked to a trigger moiety by means of a self-immolative spacer. The trigger moiety is selected from glycosyl residues and oligosaccharides, stabilizes the self-immolative spacer and is cleavable by a pathogen hydrolytic enzyme which is preferably an extracellular glycosidase (EC 3.2.1). When the trigger moiety is cleaved by the pathogen hydrolytic enzyme, the self-immolative spacer undergoes a spontaneous degradation so as to release the antifungal moiety. The invention also relates to pharmaceutical compositions comprising said prodrug and to its use in the treatment of infectious diseases.

公开(公告)号：US11696891B2

公开(公告)日：2023-07-11

申请号：US17218739

申请日：2021-03-31

申请人： Gedea Biotech AB

发明人： Ulf Ellervik ,  Olov Sterner ,  Helena Strevens ,  Sophie Manner

IPC分类号： A61K9/00 ,  A61K31/366 ,  F27D1/16 ,  F27B14/10 ,  F27B14/06 ,  A61P31/10 ,  A61K9/02 ,  H05B6/24 ,  A61K9/20 ,  A61K31/351 ,  A61K31/4164 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7004 ,  F27B14/00 ,  F27B3/12 ,  A61K31/4174 ,  A61K31/4196 ,  F27B14/08

CPC分类号： A61K9/0036 ,  A61K9/0034 ,  A61K9/02 ,  A61K9/20 ,  A61K31/351 ,  A61K31/366 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/4196 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7004 ,  A61P31/10 ,  F27B3/12 ,  F27B14/00 ,  F27B14/061 ,  F27B14/10 ,  F27D1/1626 ,  H05B6/24 ,  F27B2014/066 ,  F27B2014/0837

摘要： The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono δ-lactone, wherein the glucono δ-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono δ-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.

公开(公告)号：US20230159591A1

公开(公告)日：2023-05-25

申请号：US17756721

申请日：2020-12-04

申请人： SHANGHAI SENHUI MEDICINE CO., LTD. ,  SHANGHAI SHENGDI PHARMACEUTICAL CO., LTD. ,  JIANGSU HENGRUI MEDICINE CO., LTD.

发明人： Jian HUANG ,  Lingjian ZHU ,  Wei JIANG ,  Weicou CAO

IPC分类号： C07K7/56 ,  A61P31/10

CPC分类号： C07K7/56 ,  A61P31/10

摘要： The present invention relates to an echinocandin analogue and a preparation method therefor. The compound can be used for preventing or treating fungal infection, or for preventing, stabilizing or inhibiting fungal growth or killing fungi. An exemplary compound is represented by formula I, wherein the definitions of R1, R2, R3 and G groups are as described in the description.

公开(公告)号：US11648259B2

公开(公告)日：2023-05-16

申请号：US15773044

申请日：2016-09-14

申请人： MYCOTOX SOLUTIONS INC.

发明人： Ronald R. Marquardt ,  Srinivasa Madhyastha

IPC分类号： C12N15/115 ,  A61K31/7088 ,  A61K39/395 ,  A61K33/06 ,  A23K20/153 ,  A23L33/13 ,  A23L33/17 ,  A23K10/18 ,  A23K20/174 ,  A23K20/179 ,  A23K20/111 ,  A23K20/132 ,  A23K20/147 ,  A23K20/163 ,  A23K20/189 ,  A23K20/28 ,  A23K20/20 ,  A23K50/20 ,  A23K50/10 ,  A23K50/75 ,  A23K50/30 ,  A23K50/40 ,  C07K16/14 ,  A23K20/142 ,  A23L33/10 ,  A23K10/16 ,  A61P31/10 ,  A61K45/06

CPC分类号： A61K31/7088 ,  A23K10/16 ,  A23K10/18 ,  A23K20/111 ,  A23K20/132 ,  A23K20/142 ,  A23K20/147 ,  A23K20/153 ,  A23K20/163 ,  A23K20/174 ,  A23K20/179 ,  A23K20/189 ,  A23K20/28 ,  A23K20/30 ,  A23K50/10 ,  A23K50/20 ,  A23K50/30 ,  A23K50/40 ,  A23K50/75 ,  A23L33/10 ,  A23L33/13 ,  A23L33/17 ,  A61K33/06 ,  A61K39/395 ,  A61K45/06 ,  A61P31/10 ,  C07K16/14 ,  C12N15/115 ,  C12N2310/16

摘要： Mycotoxin-deactivating aptamers, especially DNA aptamers, bind to mycotoxins in feed and feed ingredients resulting in the reduction or elimination of toxic and carcinogenic effects of mycotoxins. The invention also discloses a composition comprising a mycotoxin-deactivating aptamer, a binding agent, a biotransforming agent and an antioxidant for detoxifying mycotoxins in feeds. In addition, the invention teaches the methods of preparing the mycotoxin-deactivating aptamer-based composition and also the methods of using it as a feed additive. Furthermore, the invention relates to the use of the mycotoxin-deactivator/s alone, or in a composition comprising the aptamers and other mycotoxin-detoxifying agents, in feeds and feed ingredients for detoxifying the major mycotoxins such as aflatoxins, deoxynivalenol, zearalenone, fumonisins and ochratoxin A.

公开(公告)号：US20190247300A1

公开(公告)日：2019-08-15

申请号：US16394937

申请日：2019-04-25

申请人： CMPD Licensing, LLC

发明人： Jay Richard Ray, II

IPC分类号： A61K9/00 ,  A61K9/08 ,  A61K47/10 ,  A61K47/26 ,  A61K47/22 ,  A61K47/02 ,  A61K47/46 ,  A61K31/496 ,  A61K45/06 ,  A61P31/10

CPC分类号： A61K9/0014 ,  A61K9/0031 ,  A61K9/0034 ,  A61K9/08 ,  A61K31/496 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/22 ,  A61K47/26 ,  A61K47/46 ,  A61P31/10

摘要： A method of treating a fungal infection may include formulating a topical treatment solution comprising combining itraconazole oral solution, 10 mg/mL, and a diluent. The itraconazole oral solution, 10 mg/mL, may include propylene glycol and at least one of cherry flavor or caramel flavor. The method may also include topically administering the topical treatment solution to the subject by contacting an infected skin surface of the subject with the topical treatment solution.